Lehman Financial Resources Inc. Buys 1,361 Shares of Sarepta Therapeutics Inc (SRPT)

Lehman Financial Resources Inc. raised its stake in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 21.3% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 7,753 shares of the biotechnology company’s stock after purchasing an additional 1,361 shares during the period. Lehman Financial Resources Inc.’s holdings in Sarepta Therapeutics were worth $431,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. boosted its stake in Sarepta Therapeutics by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 271 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in Sarepta Therapeutics by 116.4% during the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 2,474 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Sarepta Therapeutics by 39.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 977 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in Sarepta Therapeutics by 140.9% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 2,493 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in Sarepta Therapeutics during the third quarter valued at approximately $204,000. 82.41% of the stock is owned by institutional investors and hedge funds.

Shares of Sarepta Therapeutics Inc (NASDAQ SRPT) opened at $59.57 on Thursday. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. Sarepta Therapeutics Inc has a fifty-two week low of $26.96 and a fifty-two week high of $68.90. The firm has a market capitalization of $3,804.89, a P/E ratio of -29.06 and a beta of 1.49.

In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $55.89, for a total value of $372,618.63. Following the sale, the director now directly owns 13,333 shares in the company, valued at $745,181.37. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 9.60% of the company’s stock.

A number of brokerages have issued reports on SRPT. Barclays restated a “hold” rating and set a $55.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, January 23rd. William Blair restated an “outperform” rating on shares of Sarepta Therapeutics in a research report on Monday, February 5th. Royal Bank of Canada began coverage on Sarepta Therapeutics in a research report on Monday, January 22nd. They set an “outperform” rating on the stock. Leerink Swann restated an “outperform” rating and set a $77.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, January 19th. Finally, Zacks Investment Research upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and seventeen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $64.65.

TRADEMARK VIOLATION WARNING: This article was originally reported by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.themarketsdaily.com/2018/02/15/lehman-financial-resources-inc-buys-1361-shares-of-sarepta-therapeutics-inc-srpt.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply